MRK
Merck & Co., Inc.
Set alert
- YTD
- +42.05%
- 1 year
- +73.30%
- Open
- 149.55
- Prev close
- 146.33
- Mkt cap
- 368.89B
- Vol
- 12.35M
- Avg vol
- 10.29M
- EPS
- 1.26
- P/E
- 118.67
- Div yield
- 2.32%
More statistics
- Low
- 147.43
- High
- 151.35
- Forward P/E
- 16.19
- Beta
- 0.00
- Short ratio
- 2.68
- Inst. own
- 82.88%
- Dividend
- 3.40
- Ex-div date
- Sep 14, 2026
- Earnings
- Feb 2, 2027
- 50-d avg
- 146.85
- 200-d avg
- 126.52
- 1y target
- 159.60
Key statistics
- Market cap
- 368.94B
- Enterprise value
- 0
- Trailing P/E
- 118.68
- Forward P/E
- 16.19
- PEG ratio
- 2.76
- Price / sales
- 5.48
- Price / book
- 8.80
- EPS (TTM)
- 1.26
- Beta
- 0.00
- Dividend yield
- 2.32%
- Payout ratio
- 266.67%
- Profit margin
- 3.64%
- Revenue (TTM)
- 67.38B
- Revenue growth
- 4.70%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 2.47B
- Short % of float
- 1.09%
- 50-day average
- 146.85
- 200-day average
- 126.52
Analyst view
Consensus: buy
- Target (low)
- 105.00
- Target (mean)
- 159.60
- Target (high)
- 186.00
- Strong buy5
- Buy14
- Hold9
- Sell0
- Strong sell0
Next earnings
Feb 2, 2027
Expected Feb 2, 2027. Consensus EPS estimate 1.86.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 2, 2027 | Dec 30, 2026 | 1.90 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 2.09 | 2.49 | +0.40 | +19.14% |
| Aug 4, 2026 | Jun 30, 2026 | -0.27049 | -0.13 | +0.14 | +51.94% |
| Apr 30, 2026 | Mar 31, 2026 | -1.47 | -1.28 | +0.19 | +12.93% |
| Feb 3, 2026 | Dec 31, 2025 | 2.01 | 2.04 | +0.03 | +1.49% |
| Oct 30, 2025 | Sep 30, 2025 | 2.36 | 2.58 | +0.22 | +9.32% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Oct 30, 2026 | Guggenheim | main | Buy | Buy |
| Oct 26, 2026 | Barclays | main | Overweight | Overweight |
| Oct 12, 2026 | Citigroup | main | Neutral | Neutral |
| Oct 12, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Oct 8, 2026 | Cantor Fitzgerald | main | Neutral | Neutral |
About Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Website
- merck.com
News
- Elon Musk Says Eli Lilly Has ‘Some Banger Drugs Coming Out’ After CEO Dave Ricks Bets Against Vinod Khosla's Big Biotech Skepticism
- Founders Financial Securities LLC Sells 3,449 Shares of Merck & Co., Inc. $MRK
- Why Merck Stock Flew Higher on Friday
- JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $175
- Merck One of Top Large-Cap Biopharma Picks-Analyst
- Merck One of Top Large-Cap Biopharma Picks-Analyst
- RBC Capital Maintains Sector Perform on Merck & Co, Lowers Price Target to $140
- Merck Q3 Earnings Call Highlights Pipeline Progress and Raised Outlook
- Defensives Lead Sectors In Friday Trading As Growth Trails
- Lost Money on Merck & Co., Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 1.76% Share Price Drop
Your note
Sign in to keep a note on MRK — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHATTOPADHYAY SANAT | Officer | Conversion of Exercise of derivative security | Apr 28, 2026 | 200,675 |
| DAVIS ROBERT M | Chief Executive Officer | Conversion of Exercise of derivative security | Apr 28, 2026 | 450,351 |
| DELUCA RICHARD ROBERT JR. | Officer | Sale | Aug 11, 2026 | 110,167 |
| GUINDO CHIRFI | Officer | Sale | Aug 12, 2026 | 36,613 |
| LI DEAN Y | Officer | Conversion of Exercise of derivative security | Apr 28, 2026 | 94,431 |
| LITCHFIELD CAROLINE | Chief Financial Officer | Conversion of Exercise of derivative security | Apr 28, 2026 | 92,300 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.20% | 226,999,837 | 33.95B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.54% | 161,323,174 | 24.12B | Jun 29, 2026 |
| State Street Corporation | 4.88% | 120,413,256 | 18.01B | Jun 29, 2026 |
| Wellington Management Group, LLP | 3.50% | 86,249,283 | 12.90B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 2.75% | 67,738,969 | 10.13B | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.46% | 60,744,214 | 9.08B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.18% | 78,411,374 | 11.73B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.59% | 63,996,884 | 9.57B | Jun 29, 2026 |
| SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF | 1.47% | 36,188,606 | 5.41B | Aug 30, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 32,874,367 | 4.92B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 32,060,543 | 4.79B | Aug 30, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.24% | 30,514,312 | 4.56B | Sep 29, 2026 |